Results 51 to 60 of about 4,805 (202)

Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down‐regulation

Journal of Experimental & Clinical Cancer Research, 2021
Background Dedifferentiated liposarcoma (DDLPS), a tumor that lacks effective treatment strategies and is associated with poor outcomes, expresses amplified MDM2 in the presence of wild-type p53.
Valentina Zuco, Sandro Pasquali, Monica Tortoreto, Silvia Brich, Stefano Percio, Gian Paolo Dagrada, Chiara Colombo, Roberta Sanfilippo, Calogero Lauricella, Mrinal Gounder, Rihan El Bezawy, Marta Barisella, Angelo Paolo Dei Tos, Paolo Giovanni Casali, Alessandro Gronchi, Silvia Stacchiotti, Nadia Zaffaroni   +16 more
doaj   +1 more source

Cell migration through 3D confining pores: speed accelerations by deformation and recoil of the nucleus [PDF]

, 2019
Directional cell migration in dense three-dimensional (3D) environments critically depends upon shape adaptation and is impeded depending on the size and rigidity of the nucleus.
Anotida Madzvamuse, Chandrasekhar Venkataraman, Feng Wei Yang, Gonzalez RC, Jan Lammerding, Jan Schepens, Joost te Riet, Katarina Wolf, Keys J, Lammerding J, Marina Krause, Mariska te Lindert, Philipp Isermann, Ralph J. A. Maas, Wiljan Hendriks   +14 more
core   +2 more sources

MUKtwelve protocol: a phase II randomised, controlled, open, parallel group, multicentre trial of selinexor, cyclophosphamide and prednisolone (SCP) versus cyclophosphamide and prednisolone (CP) in patients with relapsed or refractory multiple myeloma. [PDF]

, 2022
INTRODUCTION: Multiple myeloma is a malignancy of plasma cells with around 6000 new cases per year in the UK. Cyclophosphamide plus prednisolone is considered a standard of care for disease and symptom control in the advanced relapsed or refractory ...
Auner, HW, Boyd, K, Brown, S, Garg, M, Hall, A, Kaiser, M, Kendall, J, Roberts, S   +7 more
core   +3 more sources

Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition [PDF]

, 2020
Altres ajuts: This work was supported by research funding from the Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias cofinanced by the European Regional Development Fund (ERDF); Fundación Asociación Española Contra el Cáncer (M.C.
Abrisqueta, Pau, Bobillo, Sabela, Boix, Joan, Bosch, Francesc, Carabia, Júlia, Castellví, Josep, Crespo, Marta, Céspedes Torrez, Dennis H., Escoda, Lourdes, Jiménez, Isabel, Martínez-Ricarte, Francisco, Nieto, Juan C., Pagès, Carlota, Palacio, Carles, Perla, Cristóbal, Puigdefàbregas, Lluís, Purroy, Noelia, Seoane Suárez, Joan   +17 more
core   +2 more sources

UPLC-MS/MS Measurement of the Effect of Isavuconazole, Itraconazole and Fluconazole on the Pharmacokinetics of Selinexor in Rats

Infection and Drug Resistance, 2020
Shuang-long Li, Yi Zhang, Qian-shi Cheng, Jun-zhe Xin, Ze-qin Dong, Xiang-jun Qiu School of Basic Medicine, Henan University of Science and Technology, Luoyang 471023, People’s Republic of ChinaCorrespondence: Xiang-jun QiuSchool of Basic Medicine,
Li S, Zhang Y, Cheng Q, Xin J, Dong Z, Qiu X   +5 more
doaj  

The Therapeutic Synergy of Selinexor and Venetoclax in Mantle Cell Lymphoma Through Induction of DNA Damage and Perturbation of the DNA Damage Response

Technology in Cancer Research & Treatment, 2023
Introduction: Mantle cell lymphoma (MCL) can be stratified into blastoid and classical subtypes based on morphological features, with the former subtype having a poorer prognosis.
Sheng Yuan MS, Wei Zuo MS, Tingting Liu MS, Huan Fu MS   +3 more
doaj   +1 more source

Navigating the Post‐BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta‐Refractory Multiple Myeloma—A Multicenter Analysis

American Journal of Hematology, EarlyView.
ABSTRACT Patients with relapsed/refractory multiple myeloma (RRMM) who are penta‐drug refractory, defined as resistant to two proteasome inhibitors, two immunomodulatory agents, and an anti‐CD38 monoclonal antibody, face a dismal prognosis, particularly after exposure to T‐cell–redirecting therapies.
Maximilian Al‐Bazaz, Winfried Alsdorf, Lisa Leypoldt, Piet Sonnemann, Christoph Schaefers, Jule Artzenroth, Marie Harzer, Abdulaziz Kamili, Leandra Bartke, Leon Cords, Jan Vorwerk, Theo Leitner, Markus Maulhardt, Kerstin Brinkert, Annamaria Brioli, Tim Richardson, Udo Holtick, Stefan M. Hillmann, Hans Salwender, Cyrus Khandanpour, Carsten Bokemeyer, Katja Weisel, Ricardo Kosch   +22 more
wiley   +1 more source

XPO1 inhibition by selinexor induces potent cytotoxicity against high grade bladder malignancies. [PDF]

, 2018
Treatment options for high grade urothelial cancers are limited and have remained largely unchanged for several decades. Selinexor (KPT-330), a first in class small molecule that inhibits the nuclear export protein XPO1, has shown efficacy as a single ...
Baek, Han Bit, Fernandez-Rubio, Aleida, Gandour-Edwards, Regina, Ghosh, Paramita M, Landesman, Yosef, Libertini, Stephen J, Lombard, Alan P, Mudryj, Maria, Nakagawa, Rachel, Nishida, Kristine, Siddiqui, Salma, Vidallo, Kathleen, Vinall, Ruth, Weiss, Robert H, Wettersten, Hiromi   +14 more
core   +1 more source

Systemic anti‐cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy

International Journal of Cancer, EarlyView.
What's New? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins, Lynn R. Gauthier, Blair H. Smith, Lesley Colvin   +3 more
wiley   +1 more source

XPO1 inhibitor selinexor suppresses homologous recombination by inhibiting E2F7 nuclear export in acute myeloid leukemia

Hematology
Objectives Aberrant nucleocytoplasmic transport mediated by Exportin 1 (XPO1) contributes to leukemogenesis, yet the molecular basis underlying the limited efficacy of the XPO1 inhibitor Selinexor in acute myeloid leukemia (AML) remains unclear.
Chunli Xu, Dandan Wang, Ruiqi Chen, Xu Feng, Feng Cheng, Yu Chen   +5 more
doaj   +1 more source